In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions. A binding assay for sGHS was established using a peptidyl sGHS (Tyr-Ala-hexarelin) which had been radioiodinated to high specific activity at the Tyr residue. Specific binding sites for 125I-labelled Tyr-Ala-hexarelin were detected mainly in membranes isolated from pituitary gland and hypothalamus, but they were also present in other brain areas such as choroid plexus, cerebral cortex, hippocampus and medulla oblongata with no sex-related differences. In contrast, negligible binding was found in the thalamus, striatum, substantia nigra, cerebellum and corpus callosum. The binding of 125I-labelled Tyr-Ala-hexarelin to membrane-binding sites is a saturable and reversible process, depending on incubation time and pH of the buffer. Scatchard analysis of the binding revealed a finite number of binding sites in the hypothalamus and pituitary gland with a dissociation constant (Kd) of (1.5 +/- 0.3) x 10(-9) and (2.1 +/- 0.4) x 10(-9) mol/l respectively. Receptor activity is sensitive to trypsin and phospholipase C digestion, suggesting that protein and phospholipids are essential for the binding of 125I-labelled Tyr-Ala-hexarelin. The binding of 125I-labelled Tyr-Ala-hexarelin to pituitary and hypothalamic membranes was displaced in a dose-dependent manner by different unlabelled synthetic peptidyl (Tyr-Ala-hexarelin, GHRP2, hexarelin, GHRP6) and non-peptidyl (MK 0677) sGHS. An inhibition of the specific binding was also observed when binding was performed in the presence of [D-Arg1-D-Phe5-D-Trp7,9-Leu11]-substance P, a substance P antagonist that has been found to inhibit GH release in response to sGHS. In contrast, no competition was observed in the presence of other neuropeptides (GHRH, somatostatin, galanin or Met-enkephalin) which have a known influence on GH release. In conclusion, the present data demonstrate that sGHS have specific receptors in human brain and pituitary gland and reinforce the hypothesis that these compounds could be the synthetic counterpart of an endogenous GH secretagogue involved in the neuroendocrine control of GH secretion and possibly in other central activities.

This article has been cited by other articles:

				T. Chen, Z. Tang, A. Yan, W. Li, and H. Lin Molecular cloning and mRNA expression analysis of two GH secretagogue receptor transcripts in orange-spotted grouper (Epinephelus coioides) J. Endocrinol., November 1, 2008; 199(2): 253 - 265. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, D. M. Keenan, and C. Y. Bowers Estimation of the size and shape of GH secretory bursts in healthy women using a physiological estradiol clamp and variable-waveform deconvolution model Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1013 - R1021. [Abstract] [Full Text] [PDF]

				A. Tropea, F. Tiberi, F. Minici, M. Orlando, M. F. Gangale, F. Romani, F. Miceli, S. Catino, S. Mancuso, M. Sanguinetti, et al. Ghrelin Affects the Release of Luteolytic and Luteotropic Factors in Human Luteal Cells J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3239 - 3245. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, M. Cosma, D. Erickson, R. Paulo, K. Mielke, L. S. Farhy, and C. Y. Bowers Tripartite Control of Growth Hormone Secretion in Women during Controlled Estradiol Repletion J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2336 - 2345. [Abstract] [Full Text] [PDF]

				B. Holst, J. Mokrosinski, M. Lang, E. Brandt, R. Nygaard, T. M. Frimurer, A. G. Beck-Sickinger, and T. W. Schwartz Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism J. Biol. Chem., May 25, 2007; 282(21): 15799 - 15811. [Abstract] [Full Text] [PDF]

				A. Baessler, M. Fischer, B. Mayer, M. Koehler, S. Wiedmann, K. Stark, A. Doering, J. Erdmann, G. Riegger, H. Schunkert, et al. Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease Hum. Mol. Genet., April 15, 2007; 16(8): 887 - 899. [Abstract] [Full Text] [PDF]

				S Pekic, M Doknic, D Miljic, M Joksimovic, J Glodic, M Djurovic, C Dieguez, F Casanueva, and V Popovic Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly. Eur. J. Endocrinol., May 1, 2006; 154(5): 659 - 666. [Abstract] [Full Text] [PDF]

				A. Baessler, A. E. Kwitek, M. Fischer, M. Koehler, W. Reinhard, J. Erdmann, G. Riegger, A. Doering, H. Schunkert, and C. Hengstenberg Association of the Ghrelin Receptor Gene Region With Left Ventricular Hypertrophy in the General Population: Results of the MONICA/KORA Augsburg Echocardiographic Substudy Hypertension, May 1, 2006; 47(5): 920 - 927. [Abstract] [Full Text] [PDF]

				D. Panidis, D. Farmakiotis, G. Koliakos, D. Rousso, A. Kourtis, I. Katsikis, C. Asteriadis, V. Karayannis, and E. Diamanti-Kandarakis Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls Hum. Reprod., August 1, 2005; 20(8): 2127 - 2132. [Abstract] [Full Text] [PDF]

				D. Erickson, D. M. Keenan, K. Mielke, K. Bradford, C. Y. Bowers, J. M. Miles, and J. D. Veldhuis Dual Secretagogue Drive of Burst-Like Growth Hormone Secretion in Postmenopausal Compared with Premenopausal Women Studied under an Experimental Estradiol Clamp J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4746 - 4754. [Abstract] [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				J. P. Camina, M. C. Carreira, S. El Messari, C. Llorens-Cortes, R. G. Smith, and F. F. Casanueva Desensitization and Endocytosis Mechanisms of Ghrelin-Activated Growth Hormone Secretagogue Receptor 1a Endocrinology, February 1, 2004; 145(2): 930 - 940. [Abstract] [Full Text] [PDF]

				M. Volante, E. Allia, E. Fulcheri, P. Cassoni, E. Ghigo, G. Muccioli, and M. Papotti Ghrelin in Fetal Thyroid and Follicular Tumors and Cell Lines: Expression and Effects on Tumor Growth Am. J. Pathol., February 1, 2003; 162(2): 645 - 654. [Abstract] [Full Text] [PDF]

				M. Volante, E. Fulcheri, E. Allia, M. Cerrato, A. Pucci, and M. Papotti Ghrelin Expression in Fetal, Infant, and Adult Human Lung J. Histochem. Cytochem., August 1, 2002; 50(8): 1013 - 1021. [Abstract] [Full Text] [PDF]

				F. Broglio, E. Arvat, A. Benso, C. Gottero, F. Prodam, S. Grottoli, M. Papotti, G. Muccioli, A. J. van der Lely, R. Deghenghi, et al. Endocrine Activities of Cortistatin-14 and Its Interaction with GHRH and Ghrelin in Humans J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3783 - 3790. [Abstract] [Full Text] [PDF]

				V. Tolle, M.-H. Bassant, P. Zizzari, F. Poindessous-Jazat, C. Tomasetto, J. Epelbaum, and M.-T. Bluet-Pajot Ultradian Rhythmicity of Ghrelin Secretion in Relation with GH, Feeding Behavior, and Sleep-Wake Patterns in Rats Endocrinology, April 1, 2002; 143(4): 1353 - 1361. [Abstract] [Full Text] [PDF]

				M. Volante, E. AllIa, P. Gugliotta, A. Funaro, F. Broglio, R. Deghenghi, G. Muccioli, E. Ghigo, and M. Papotti Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1300 - 1308. [Abstract] [Full Text] [PDF]

				C. Ghe, P. Cassoni, F. Catapano, T. Marrocco, R. Deghenghi, E. Ghigo, G. Muccioli, and M. Papotti The Antiproliferative Effect of Synthetic Peptidyl GH Secretagogues in Human CALU-1 Lung Carcinoma Cells Endocrinology, February 1, 2002; 143(2): 484 - 491. [Abstract] [Full Text] [PDF]

				M. Papotti, P. Cassoni, M. Volante, R. Deghenghi, G. Muccioli, and E. Ghigo Ghrelin-Producing Endocrine Tumors of the Stomach and Intestine J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5052 - 5059. [Abstract] [Full Text] [PDF]

				R. G. Gondo, M. H. Aguiar-Oliveira, C. Y. Hayashida, S. P. A. Toledo, N. Abelin, M. A. Levine, C. Y. Bowers, A. H. O. Souza, R. M. C. Pereira, N. L. Santos, et al. Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3279 - 3283. [Abstract] [Full Text] [PDF]

				P. Cassoni, M. Papotti, C. Ghè, F. Catapano, A. Sapino, A. Graziani, R. Deghenghi, T. Reissmann, E. Ghigo, and G. Muccioli Identification, Characterization, and Biological Activity of Specific Receptors for Natural (Ghrelin) and Synthetic Growth Hormone Secretagogues and Analogs in Human Breast Carcinomas and Cell Lines J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1738 - 1745. [Abstract] [Full Text]

				S. M. Anderson, N. Shah, W. S. Evans, J. T. Patrie, C. Y. Bowers, and J. D. Veldhuis Short-Term Estradiol Supplementation Augments Growth Hormone (GH) Secretory Responsiveness to Dose-Varying GH-Releasing Peptide Infusions in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 551 - 560. [Abstract] [Full Text]

				M. Papotti, C. Ghè, P. Cassoni, F. Catapano, R. Deghenghi, E. Ghigo, and G. Muccioli Growth Hormone Secretagogue Binding Sites in Peripheral Human Tissues J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3803 - 3807. [Abstract] [Full Text]

				S. Tullin, B. S. Hansen, M. Ankersen, J. Moller, K. A. von Cappelen, and L. Thim Adenosine Is an Agonist of the Growth Hormone Secretagogue Receptor Endocrinology, September 1, 2000; 141(9): 3397 - 3402. [Abstract] [Full Text] [PDF]

				A.-C. A. R. Pinto, M. R. D. Silva, M. R. Martins, E. Brunner, and A.-M. J. Lengyel Effects of Short-Term Glucocorticoid Deprivation on Growth Hormone (GH) Response to GH-Releasing Peptide-6: Studies in Normal Men and in Patients with Adrenal Insufficiency J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1540 - 1544. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				E. Ghigo, L. Gianotti, E. Arvat, J. Ramunni, M. R. Valetto, F. Broglio, M. Rolla, F. Cavagnini, and E. E. Müller Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Growth Hormone (GH) Secretion, Both Spontaneous and Stimulated by GH-Releasing Hormone or Hexarelin, a Peptidyl GH Secretagogue, in Humans J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 285 - 290. [Abstract] [Full Text]

				E. Arvat, R. Giordano, J. Ramunni, G. Arnaldi, A. Colao, R. Deghenghi, G. Lombardi, F. Mantero, F. Camanni, and E. Ghigo Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4207 - 4211. [Abstract] [Full Text]